|Chemical name||Elafibranor; GFT505; GFT-505; GFT 505;|
|Molecular Weight||384.489 g/mol|
|Appearance||White to Off-white powder|
|Solubility||Soluble in DMSO|
|Storage Condition||0 – 4 C for short term (days to weeks), or -20 C for long term (months).|
|Application||Elafibranor (code name GFT505) is a multimodal and pluripotent medication for treatment of atherogenic dyslipidemia for an overweight patient with or without diabetes.|
02 Base Information
03 GFT505 (ELAFIBRANOR) General Description
Elafibranor(INN, code name GFT505) is an experimental medication that is being studied and developed by Genfit for the treatment of cardiometabolic diseases including diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).
04 GFT505 (ELAFIBRANOR) History
Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. We assessed the safety and efficacy of elafibranor in an international, randomized, double-blind placebo-controlled trial of patients with nonalcoholic steatohepatitis (NASH).
05 GFT505 (ELAFIBRANOR) Mechanism Of Action
GFT505 is an oral treatment that acts on the 3 sub-types of PPAR (PPARa, PPARg, PPARd) with a preferential action on PPARa. It has a sophisticated mechanism of action. It is able to differentially recruit cofactors to the nuclear receptor, which subsequently lead to differential regulation of genes and biological effect. Therefore, the ability to identify and profile the activity of selective nuclear receptor modulator (SNuRMs) is a powerful approach to select innovative drug candidates with improved efficacy and diminished side effects. These pluripotent and multimodal molecules have significant positive effects on obesity, insulin-resistance and diabetes, atherosclerosis, inflammation, and the lipid triad (increasing of HDL cholesterol, lowering of triglycerides and LDL cholesterol).
06 GFT505 (ELAFIBRANOR) Application
Elafibranor (code name GFT505) is a multimodal and pluripotent medication for treatment of atherogenic dyslipidemia for an overweight patient with or without diabetes. It is an oral treatment that acts on the 3 sub-types of PPAR (PPARa, PPARg, PPARd) with a preferential action on PPARa. As of February 2016, elafibranor has completed 8 clinical trials and a phase III is in progress.
07 GFT505 (ELAFIBRANOR) More research
A Study to Evaluate the Efficacy and Safety of GFT505 once daily on Steatohepatitis in Patients with Non-Alcoholic Steatohepatitis (NASH). A Multicentre, Randomized, Double Blind, Placebo-Controlled study, with an adaptive design to allow for initial GFT505 80mg dosing versus placebo, followed by a second phase including GFT505 120mg dose, after review of 6-month safety analysis of the 80mg data on at least 50% of patients.
08 GFT505 (ELAFIBRANOR) Document Download
09 GFT505 (ELAFIBRANOR) Reference
- 01. Overview
- 02. Base Information
- 03. GFT505 (ELAFIBRANOR) General Description
- 04. GFT505 (ELAFIBRANOR) History
- 05. GFT505 (ELAFIBRANOR) Mechanism Of Action
- 06. GFT505 (ELAFIBRANOR) Application
- 07. GFT505 (ELAFIBRANOR) More research
- 08. GFT505 (ELAFIBRANOR) Document Download
- 09. GFT505 (ELAFIBRANOR) Reference